ZNF384 and acute lymphoblastic leukemia: Outcomes for EP300-ZNF384 patients compared favourably to other pre-B-ALL patients (27.2% 5-year survival; n = 61; p = 0.083) and Ph-like ALL patients14 (10.3% 5-year survival, n = 24; p = 0.019) (Fig. 1c), noting that four of the eight EP300-ZNF384 patients were transplanted.